Financial Performance - Total revenues for the three months ended March 31, 2025, were $745.1 million, an increase of 14.8% compared to $648.8 million for the same period in 2024[87] - Net income for the three months ended March 31, 2025, was $185.7 million, up from $88.7 million in the same period in 2024, representing a 109.5% increase[87] - Net product revenues increased to $734.6 million for the three months ended March 31, 2025, compared to $637.8 million for the same period in 2024, a growth of 15.2%[95] Sales Performance - VOXZOGO sales reached $213.7 million for the three months ended March 31, 2025, up 39.8% from $152.9 million in the same period in 2024[95] - PALYNZIQ sales increased by 23.2% to $93.3 million for the three months ended March 31, 2025, compared to $75.7 million in the same period in 2024[95] Research and Development - Research and development (R&D) expenses were $158.7 million for the three months ended March 31, 2025, down from $205.0 million in the same period in 2024, a decrease of 22.5%[87] - The company completed enrollment of its pivotal Phase 3 study with VOXZOGO in hypochondroplasia in April 2025[91] - The pivotal study with PALYNZIQ for adolescents met its primary efficacy endpoint, demonstrating a statistically significant lowering in blood Phe levels[92] - Total R&D expense decreased to $158.7 million in Q1 2025 from $205.0 million in Q1 2024, a reduction of $46.3 million or 22.6%[106] Operating Expenses - Total SG&A expense decreased to $206.1 million in Q1 2025 from $225.9 million in Q1 2024, a reduction of $19.8 million or 8.8%[108] Cash Flow and Liquidity - Net cash provided by operating activities increased to $174.4 million in Q1 2025 from $47.0 million in Q1 2024, an increase of $127.4 million[120] - Cash and cash equivalents increased to $1,048.8 million as of March 31, 2025, up from $942.8 million as of December 31, 2024, an increase of $106.0 million[118] - Total cash, cash equivalents, and investments increased to $1,779.0 million as of March 31, 2025, up from $1,658.9 million as of December 31, 2024, an increase of $120.1 million[118] Tax and Interest - Provision for income taxes increased to $52.4 million in Q1 2025 from $16.9 million in Q1 2024, an increase of $35.5 million[117] - Interest expense decreased to $2.9 million in Q1 2025 from $3.5 million in Q1 2024, a reduction of $0.6 million or 17.1%[114] - Other income (expense), net decreased to $(2.0) million in Q1 2025 from $1.3 million in Q1 2024, a decrease of $3.3 million[115] Obligations and Debt - The company had purchase obligations of approximately $586.6 million as of March 31, 2025, with $299.8 million expected to be paid in 2025[125] - The company’s convertible debt as of March 31, 2025 amounted to $600.0 million, due in May 2027[123]

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $0.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 20.21%. A quarter ago, it was expected that this rare disease biopharmaceutical would post earnings of $0.73 per share when it actually produced earnings of $0.92, delivering a surprise of 26.03%.Over the l ...

Financial Data and Key Metrics Changes - BioMarin reported a revenue growth of 15% in Q1 2025, totaling $745 million compared to the same period last year [12] - Non-GAAP earnings per share reached $1.13, representing a 59% year-over-year increase, indicating significant profitability expansion [5][19] - Non-GAAP operating margin expanded to 35.7%, an increase of 11.9 percentage points year-over-year [15] Business Line Data and Key Metrics Changes - Voxzogo's global revenue reached $214 million, a 40% increase year-over-year, continuing its strong growth trajectory since approval [13] - Revenue from the Enzyme Therapies business unit grew 8% year-over-year to $484 million, with Palynziq contributing a 22% increase compared to Q1 2024 [13][22] - Full-year revenue expectations for Voxzogo are between $900 million and $950 million, representing a 26% growth at the midpoint [14] Market Data and Key Metrics Changes - Approximately two-thirds of BioMarin's total revenues originate from outside the United States, providing insulation from U.S. macroeconomic conditions [7][9] - The company is analyzing potential exposure to pharmaceutical tariffs and believes its global revenue base offers protection against such impacts [8][9] Company Strategy and Development Direction - BioMarin is focused on implementing changes to its strategy and operating model announced in September 2024, aiming for record full-year performance in 2025 [6][11] - The company is advancing its innovation strategy, with pivotal studies for Voxzogo and plans for new product applications in the second half of 2025 [10][24] - BioMarin aims to leverage its established global capabilities to support growth and innovation, particularly in rare disease treatments [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in BioMarin's ability to navigate market uncertainties due to its focus on rare conditions and strong cash generation [6][7] - The company anticipates continued strong performance and innovation in the coming quarters, supported by its strategic transformation [11][19] Other Important Information - Non-GAAP R&D expenses were $147 million, lower than the same quarter in 2024, reflecting a reprioritization of R&D efforts [14] - Non-GAAP SG&A expenses decreased to $183 million due to cost transformation initiatives [15] Q&A Session Summary Question: Will Q2 revenue for Voxzogo decline? - Management indicated that while Q1 showed growth, Q2 revenue may appear flat due to global order dynamics, with expectations for stronger growth in the second half of the year [35][36] Question: How could potential U.S. tariffs impact financials? - Management stated that current guidance includes modest impacts from existing tariffs, but they are modeling various scenarios for potential future tariffs [36][37] Question: What strategies are being implemented to drive further adoption of Voxzogo? - The company is focusing on increasing awareness and expanding the prescriber base, particularly among pediatric endocrinologists, to drive adoption across all age groups [55][56] Question: What is the timeline for BMN 333 and its potential indications? - BMN 333 is in a Phase I study, with plans for pivotal studies in 2027, and the company is evaluating its future role in additional indications [84] Question: How have U.S. versus ex-U.S. sales evolved for Voxzogo? - Approximately 75% of Voxzogo revenues come from outside the U.S., and this split is expected to fluctuate as the brand matures [88]

Financial Data and Key Metrics Changes - BioMarin reported a revenue growth of 15% in Q1 2025, totaling $745 million compared to the same period last year [14] - Non-GAAP earnings per share reached $1.13, representing a 59% year-over-year increase, indicating significant profitability expansion [6][20] - Non-GAAP operating margin expanded to 35.7%, an increase of 11.9 percentage points year over year, driven by strong revenue performance and a reset in spending [18][20] - Positive operating cash flow was $174 million, a 271% increase over Q1 2024, supporting future growth investments [22] Business Line Data and Key Metrics Changes - VOXZOGO's global revenue reached $214 million, a 40% increase year over year, continuing its strong growth trajectory since approval [15] - Revenue from the Enzyme Therapies business unit grew 8% year over year to $484 million, with Palynziq contributing a 22% increase compared to Q1 2024 [15][27] - The company expects VOXZOGO full-year revenues to be between $900 million and $950 million, representing a 26% growth at the midpoint [16] Market Data and Key Metrics Changes - Approximately two-thirds of BioMarin's total revenues originate from outside the United States, providing insulation from U.S. macroeconomic conditions [9][10] - The company is focused on expanding access to VOXZOGO in more than 60 countries by 2027, with current access in 49 countries [24][26] Company Strategy and Development Direction - BioMarin is implementing a strategic transformation aimed at enhancing growth and profitability, with a focus on innovation and expansion [8][13] - The company is making progress on its innovation strategy, including pivotal studies for new products like Voxogo and Palynziq [12][28] - BioMarin is exploring business development opportunities aligned with its strengths in genetically defined conditions and clinical stage assets [45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating uncertainties in the pharmaceutical sector, citing the company's strong fundamentals and global revenue base [9][10] - The company anticipates continued strong performance and cash generation, supporting its growth agenda for 2025 and beyond [22][13] Other Important Information - BioMarin's R&D expenses were $147 million in Q1 2025, lower than the same quarter in 2024, reflecting a reprioritization strategy [17] - SG&A expenses decreased to $183 million year over year, attributed to cost transformation initiatives [18] Q&A Session Summary Question: Will Q2 revenue for VOXZOGO decline? - Management indicated that while revenue growth is expected to be stronger in the second half of the year, Q2 may show a slight decline due to global order dynamics [36][37] Question: How could U.S. tariffs impact financials? - Management stated that current guidance includes modest impacts from existing tariffs, but they are evaluating potential future scenarios and mitigation strategies [39][40] Question: What strategies are being implemented to drive further adoption of VOXZOGO? - The company is focusing on increasing awareness and expanding the prescriber base, particularly among pediatric endocrinologists, to drive adoption across all age groups [55][56] Question: What is the timeline for BMN 333 and its potential indications? - Management anticipates data from ongoing studies in 2027, with plans for pivotal studies based on the outcomes of BMN 333 [84] Question: How does the U.S. versus ex-U.S. sales for VOXZOGO compare? - Approximately 75% of VOXZOGO revenues come from outside the U.S., with expectations for this split to fluctuate as the brand matures [88]

Financial Performance - Total revenues for Q1 2025 reached $745 million, a 15% year-over-year increase[13] - VOXZOGO revenues experienced substantial growth, increasing by 40% year-over-year to $214 million[14] - Enzyme Therapies revenues grew by 8% year-over-year, driven by PALYNZIQ's 22% growth[14, 17] - Non-GAAP Diluted EPS increased by 59% year-over-year, reaching $1.13[14] - GAAP Diluted Earnings per Share (EPS) showed significant improvement, increasing by 107% to $0.95[14] - Non-GAAP Operating Margin percentage was 35.7%, an increase of 11.9 percentage points year-over-year[14] Guidance and Pipeline - Full-year 2025 guidance reaffirmed for Total Revenues ($3.1 billion to $3.2 billion), Non-GAAP Operating Margin (32% to 33%), and Non-GAAP Diluted EPS ($4.20 to $4.40)[20] - Initial data for BMN 351 for DMD is expected in the second half of 2025[17] - Pivotal study with VOXZOGO in hypochondroplasia fully enrolled in April 2025, with potential launch in 2027[17] - Positive pivotal topline results for PALYNZIQ in adolescents ages 12-17 shared in April, supporting planned submissions to regulatory authorities in the U.S and EU in 2H'25[17]

Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance First Quarter 2025 Total Revenues of $745 million (+15% Y/Y and +17% at Constant Currency Y/Y) First Quarter 2025 Business Highlights Innovation 2 First Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $0.95 (+107% Y/Y) First Quarter 2025 Non-GAAP Diluted EPS of $1.13 (+59% ...

SAN RAFAEL, Calif., April 17, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, 2025, at 4:30 p.m. ET to discuss first quarter 2025 financial results and provide a general business update.Dial-in Number U.S. / Canada Dial-in Number: 888-596-4144International Dial-in Number: 646-968-2525Conference Call ID: 4327591U.S. / Canada Replay Dial-in Numbe ...

Market Overview - The stock market has experienced historic volatility, with the S&P 500 losing 10.5% in just two trading days, marking its fifth-largest two-day decline in 75 years [2] - President Trump's temporary reversal of tariff policies led to significant single-session gains for major indices on April 9, with the Dow Jones increasing by 2,963 points, S&P 500 by 474 points, and Nasdaq Composite by 1,857 points, all record highs [3] Investment Opportunities - Despite the market being historically pricey, price dislocations have emerged, allowing for the purchase of undervalued stocks [4] Pfizer - Pfizer is viewed as mispriced, with concerns over potential tariffs on pharmaceuticals being considered overblown; the company was nearing an 8% dividend yield [5] - Sales from COVID-19 therapies dropped from over $56 billion in 2022 to approximately $11 billion last year, yet Pfizer's net sales increased by 52% to $63.6 billion from 2020 to 2024 [6][7] - The acquisition of Seagen is expected to enhance Pfizer's growth, with a forward P/E ratio just above 7 being attractive [8] Sirius XM Holdings - Sirius XM is identified as having a price dislocation, with its unique position as the only licensed satellite-radio operator providing it with pricing power [9][10] - The company generates 76% of its net sales from subscriptions, making its cash flow more predictable during economic downturns; shares were trading at a forward P/E of 6, the lowest since going public [12] Intel - Intel's shares are trading below book value, presenting a buying opportunity despite challenges from competitors [13] - The company remains a dominant player in CPUs for laptops and desktops, and new CEO Lip-Bu Tan is expected to improve operations and margins [15] - Intel's potential in AI remains, despite current struggles in the market [16] Fastly - Fastly is recognized for its content delivery network and security solutions, with a compelling long-term outlook despite recent growth disappointments [18][19] - The company has a net retention rate of 102% and a consistent annual revenue retention rate above 99%, indicating customer loyalty [20] - Shares are trading below book value and at a low sales multiple, making it an attractive investment [21] BioMarin Pharmaceutical - BioMarin focuses on orphan-disease therapies, which leads to predictable demand and strong pricing power [23] - The company reported $2.85 billion in sales last year, an 18% increase, with its top-selling drug Voxzogo contributing significantly [24] - BioMarin's valuation is at historic lows, with a forecasted P/E of just over 10 for 2026 [25] PubMatic - PubMatic is positioned well in the digital advertising space, focusing on connected TV and mobile, with a significant growth segment [28] - The company has developed its own cloud infrastructure, which is expected to enhance margins as it scales [29] - With a strong cash position and positive operating cash flow for a decade, shares were valued at 10 times forecast EPS, presenting a clear price dislocation [30]

Core Viewpoint - BioMarin Pharmaceutical (BMRN) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, supported by a strong history of exceeding expectations [1]. Group 1: Earnings Performance - BioMarin has a solid track record of surpassing earnings estimates, with an average surprise of 21.35% over the last two quarters [2]. - In the most recent quarter, BioMarin reported earnings of $0.92 per share, exceeding the expected $0.73 per share by 26.03% [3]. - For the previous quarter, the company reported $0.91 per share against an expectation of $0.78 per share, resulting in a surprise of 16.67% [3]. Group 2: Earnings Estimates and Predictions - Recent changes in earnings estimates for BioMarin have been favorable, with a positive Zacks Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [6]. - The combination of a positive Earnings ESP and a Zacks Rank 2 (Buy) suggests that another earnings beat is likely [9]. - BioMarin currently has an Earnings ESP of +6.51%, reflecting increased analyst optimism regarding the company's earnings prospects [9]. Group 3: Importance of Earnings ESP - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [7]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate being more reflective of recent analyst revisions [8]. - It is crucial to check a company's Earnings ESP before quarterly releases to enhance the likelihood of successful investment decisions [10].

Company Overview - BioMarin Pharmaceutical (BMRN) shares increased by 6.3% to $59.43, following a significant trading volume, contrasting with a 20.7% loss over the past four weeks [1] - The rise in share price was influenced by President Trump's announcement of a 90-day pause on tariffs against non-retaliating countries [1] Earnings Expectations - BioMarin is projected to report quarterly earnings of $0.95 per share, reflecting a year-over-year increase of 33.8% [2] - Expected revenues for the upcoming quarter are $738.75 million, which is a 13.9% increase compared to the same quarter last year [2] Earnings Estimate Revisions - The consensus EPS estimate for BioMarin has been slightly revised higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [3] - The stock currently holds a Zacks Rank of 2 (Buy), suggesting favorable market sentiment [3] Industry Comparison - BioMarin operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Merus N.V. (MRUS), saw a 13.4% increase in its stock price, closing at $39.56 [3] - Merus' consensus EPS estimate has decreased by 3.7% to -$1.17, representing a significant year-over-year decline of 98.3% [4]